Vimpat
Seizures, Epilepsy, Status Epilepticus
Treatment
5 Active Studies for Vimpat
Treatment for
Seizures
What is Vimpat
Lacosamide
The Generic name of this drug
Treatment Summary
Lacosamide is a medication used to treat partial-onset seizures and nerve pain caused by diabetes. It is known to affect only active neurons, which are typically at the center of an epileptic seizure, unlike other antiepileptic drugs that slow down neuron recovery time. Lacosamide is considered a functionalized amino acid that has been tested in the maximal electroshock seizure test.
Vimpat
is the brand name
Vimpat Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Vimpat
Lacosamide
2008
115
Effectiveness
How Vimpat Affects Patients
Lacosamide has been shown to reduce the frequency of seizures. Research suggests that taking higher doses (more than 400 mg per day) does not necessarily result in greater benefits.
How Vimpat works in the body
Lacosamide is thought to reduce pain by inhibiting sodium channels. It may be selective for neurons that are already overactive, which is what happens in pain states. Lacosamide binds to a protein called CRMP-2, which is found in the nervous system and helps control how nerves grow. We don't yet understand how this helps with seizure control.
When to interrupt dosage
The dose of Vimpat is contingent upon the diagnosed condition. The amount of dosage also relies on the administration mode (e.g. Kit; Tablet, film coated - Oral or Oral) presented in the table beneath.
Condition
Dosage
Administration
Seizures
, 50.0 mg, 200.0 mg, 150.0 mg, 100.0 mg, 10.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Syrup, Intravenous, Syrup - Oral, Solution, Solution - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous
Epilepsy
, 50.0 mg, 200.0 mg, 150.0 mg, 100.0 mg, 10.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Syrup, Intravenous, Syrup - Oral, Solution, Solution - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous
Status Epilepticus
, 50.0 mg, 200.0 mg, 150.0 mg, 100.0 mg, 10.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Syrup, Intravenous, Syrup - Oral, Solution, Solution - Oral, Injection, Injection - Intravenous, Tablet, Tablet - Oral, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous
Warnings
There are 20 known major drug interactions with Vimpat.
Common Vimpat Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Oliceridine
Major
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Lacosamide is combined with Oliceridine.
Thalidomide
Major
Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Agmatine
Minor
Lacosamide may increase the bradycardic activities of Agmatine.
Vimpat Novel Uses: Which Conditions Have a Clinical Trial Featuring Vimpat?
Three investigations are presently underway to assess the potential of Vimpat in providing therapeutic benefit for Status Epilepticus (Convulsive).
Condition
Clinical Trials
Trial Phases
Seizures
5 Actively Recruiting
Phase 3, Phase 2, Phase 1
Epilepsy
0 Actively Recruiting
Status Epilepticus
0 Actively Recruiting
Vimpat Reviews: What are patients saying about Vimpat?
5
Patient Review
11/10/2022
Vimpat for Repeated Seizures with Unconsciousness Between Episodes
4.3
Patient Review
1/23/2022
Vimpat for Additional Medication for Tonic-Clonic Epilepsy
4.3
Patient Review
1/28/2022
Vimpat for Additional Medication to Treat Partial Seizures
2.7
Patient Review
3/19/2022
Vimpat for Additional Medication to Treat Partial Seizures
2.7
Patient Review
1/11/2019
Vimpat for Simple Seizure
2.3
Patient Review
4/24/2019
Vimpat for Additional Medication to Treat Partial Seizures
2
Patient Review
11/20/2018
Vimpat for Additional Medication to Treat Partial Seizures
1.3
Patient Review
1/4/2022
Vimpat for Additional Medication for Tonic-Clonic Epilepsy
1
Patient Review
6/5/2022
Vimpat for Simple Seizure
Patient Q&A Section about vimpat
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What does VIMPAT do to the brain?
"Vimpat contains the active ingredient lacosamide, which is a medicine used to treat epilepsy by stabilizing electrical activity in the brain. Nerve cells in the brain and nerves communicate with each other through electrical signals."
Answered by AI
Are VIMPAT and Keppra the same?
"Keppra and Vimpat work similarly in the brain to decrease abnormal electrical activity.
Keppra and Vimpat are two drugs that are often used to treat seizures in people with epilepsy. These drugs work by decreasing the abnormal electrical activity in the brain."
Answered by AI
What is the drug VIMPAT used for?
"VIMPAT is a prescription medicine used to treat partial-onset seizures in people 1 month of age and older. It may be used with other medicines to treat primary generalized tonic-clonic seizures in people 4 years of age and older."
Answered by AI
Why is VIMPAT a narcotic?
"Selling or giving away VIMPAT is against the law.
VIMPAT is a Schedule V Controlled Substance because it has a danger of being abused and could lead to drug dependence. You should keep your VIMPAT in a safe place in order to protect it from theft. You should never give VIMPAT to anyone else because it could harm them; selling or giving away VIMPAT is against the law."
Answered by AI